Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.40B | 1.05B | 1.23B | 1.27B | 1.22B |
Gross Profit | 753.36M | 551.31M | 770.75M | 806.28M | 781.07M |
EBITDA | 260.87M | 193.05M | 229.06M | 2.13B | 279.43M |
Net Income | 93.10M | 16.70M | 51.28M | 1.99B | 78.53M |
Balance Sheet | |||||
Total Assets | 2.62B | 2.89B | 2.78B | 3.64B | 3.25B |
Cash, Cash Equivalents and Short-Term Investments | 216.84M | 171.00M | 189.30M | 277.53M | 414.54M |
Total Debt | 227.30M | 204.14M | 163.49M | 267.14M | 156.71M |
Total Liabilities | 1.07B | 930.07M | 939.50M | 1.25B | 1.14B |
Stockholders Equity | 1.65B | 2.04B | 1.92B | 2.46B | 2.15B |
Cash Flow | |||||
Free Cash Flow | 34.45M | -45.89M | 69.81M | -160.04M | -139.23M |
Operating Cash Flow | 242.01M | 110.08M | 283.63M | 210.68M | 218.91M |
Investing Cash Flow | -192.36M | -145.22M | -256.05M | -370.28M | -523.74M |
Financing Cash Flow | -1.96M | 13.44M | -128.60M | 60.97M | -9.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | HK$948.02M | 10.18 | 5.04% | 2.80% | 32.95% | 456.69% | |
52 Neutral | $7.63B | 0.11 | -62.96% | 2.08% | 16.16% | 0.31% | |
― | $1.59B | ― | -4.93% | 2.69% | ― | ― | |
74 Outperform | HK$6.35B | 6.97 | 11.61% | 0.83% | -18.09% | -15.08% | |
73 Outperform | HK$2.04B | 3.34 | 18.33% | 5.33% | -9.95% | 67.56% | |
70 Outperform | HK$10.90B | 12.10 | 8.89% | 0.58% | 4.91% | -11.80% | |
65 Neutral | HK$14.08B | 26.93 | 5.88% | ― | -42.02% | -76.29% |
Lee’s Pharmaceutical Holdings Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic growth.